CA3217892A1 — Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use
Assigned to Nurix Therapeutics Inc · Expires 2022-11-10 · 4y expired
What this patent protects
Provided herein are heterobifunctional compounds which find utility as modulators of targeted ubiquitination. Also provided herein are pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds, and compositions in the treatment of vario…
USPTO Abstract
Provided herein are heterobifunctional compounds which find utility as modulators of targeted ubiquitination. Also provided herein are pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds, and compositions in the treatment of various diseases, conditions, or disorders.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.